Jeff Chamberlain receives 2024 MDA Legacy Award
The Muscular Dystrophy Association (MDA) today announced Jeffrey Chamberlain, Ph.D., a leading professor in gene therapy focused on Duchenne muscular dystrophy (DMD) at the UW Institute for Stem Cell and Regenerative Medicine, will receive the 2024 MDA Legacy Award for Achievement in Research, for his achievements in translational research.
"It's a true honor to receive the 2024 MDA Legacy Award for Achievement in Research for my work in translational research and a real testament to the continuous support I’ve received from Muscular Dystrophy Association over the past three decades," said Chamberlain.
"I received my very first grant from the Muscular Dystrophy Association – they've been with me from the start and continue to fund my research and serve as a trusted resource. This award is one of the highlights of my career without question. I grew up watching the MDA Telethon when I was a little kid, and I was always intrigued by the idea of muscular dystrophy. After almost 40 years, I am developing gene therapies for Duchenne muscular dystrophy, and we’ve seen real progress and results. Receiving this reward is really a culmination of many years of dedicated work. I’m excited about the 2024 MDA Clinical & Scientific Conference and all we’ll learn and share as a community and all the developments and achievements that are to come."
The MDA Legacy Award for Achievement in Research is an annual recognition for outstanding accomplishments in neuromuscular disease research. This award is the MDA's highest award for contributions to the fight against muscular dystrophy. Chamberlain will be honored at the MDA's annual Clinical and Scientific Conference in March.